Skip to content

Clinical evaluation of Misatol (MK615), extract from Japanese apricot "Prunus Ume", for ulcerative colitis patients: A mono-center open trial.

Clinical evaluation of Misatol (MK615), extract from Japanese apricot "Prunus Ume", for ulcerative colitis patients: A mono-center open trial. - Unique supplement, Misatol, for ulcerative colitis; a preliminary clinical Evaluation Trial (UME-trial)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003941
Enrollment
20
Registered
2010-07-26
Start date
2010-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Patients should take Misatol (6.5g/pack) 2 packs (before breakfast and dinner) per day during one year. Patients should not take Misatol during one year.

Sponsors

Department of lower gastroenterology, Hyogo College of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patient who have diagnosed as ulcerative colitis. 2) Steroid refractory patients who experienced deterioration within at least last one year. 3) Patients who response other treatment. The Patients Lichiger index score decrease from higher than 4 to smaller than 3 and keep smaller 3 within three week. 4) Patients who could continue Misatol intake 2packs per day during one year. 5) Patients who could visit a research doctor once a month.

Exclusion criteria

Exclusion criteria: 1. Patients under 18 y.o and/or more than 76 y.o. 2. Patients who have been enrolled other clinical trial. 3. Patients who have not jugged as eligible by their doctors.

Design outcomes

Primary

MeasureTime frame
Lichtiger's CAI(clinical activity index) are evaluated at every monthly visit. Endoscopic UC activity is diagnosed by the Mayo index. Clinical and endoscopic activities are compared between taking and not-taking Misatol groups at 4, 24, and 48 weeks; also probability of sustained remission ratio of these groups should be analyzed and compared using the Kaplan Meier method.

Secondary

MeasureTime frame
Secretions of the peripheral cytokines are compared between pre and post trial. Safety observation is conducted at each visit, but within the coverage of national health insurance policy. Blood samplings Complete blood cell counts, AST (GOT), ALT (GPT), gamma-GTP, Alkaline phosphatase (ALP), Lactate dehydrogenase (LDH), Total-bilirubin, Total-cholesterol, etc.

Countries

Japan

Contacts

Public ContactKen Fukunaga

Hyogo College of Medicine Department of lower gastroenterology

kebe@hyo-med.ac.jp0798-45-6662

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026